ARA-290 vs BPC-157
ARA-290 (cibinetide) is built from erythropoietin but does not raise red-cell counts; it targets the innate repair receptor and was trialled in neuropathy. BPC-157 is a gastric peptide studied in preclinical tissue-healing models.
ARA-290
An 11-amino-acid peptide from erythropoietin’s helix B that activates the "innate repair receptor" without stimulating red-cell production.
BEST STUDIED FOR
Repair & immune
Read the cited profile →
BPC-157
BPC-157 is a synthetic pentadecapeptide derived from a protective sequence found in human gastric juice.
BEST STUDIED FOR
Preclinical soft-tissue and gut-healing models
R489View product →
Side by side · to buy
Price, purity and dispatch
| Compare | ARA-290 | BPC-15710mg |
|---|---|---|
| Price | — | R489 |
| Cost per mg | — | R48.9 / mg |
| Purity (Janoshik) | — | 99.427%HPLC, published |
| Stock | — | In stock |
| Dispatch | — | Same dayPaid before 12:00, Mon–Fri |
| Certificate | — | View CoA → |
| Literature | 3 papers | 4 papers → |
| Research focus | Repair & immune | Preclinical soft-tissue and gut-healing models |
| Read the cited profile |
Prices are read live from the catalogue. Cost per mg is the vial price over its stated mg. Purity is shown only where the certificate is published. Every compound is supplied for laboratory research only.
SIDE BY SIDE
| ARA-290 | BPC-157 | |
|---|---|---|
| The key difference | EPO-derived innate-repair-receptor agonist | Gastric-derived pentadecapeptide |
| Class | Repair & immune | Repair & immune |
| Mechanism | ARA-290 targets a heteromer of the EPO receptor and the β-common receptor (CD131), switching on anti-inflammatory and tissue-protective signalling while avoiding EPO’s haematopoietic (and thrombotic) effects. | BPC-157 is a synthetic pentadecapeptide derived from a protective sequence found in human gastric juice. |
| Status | Phase 2 trials in sarcoidosis- and diabetes-associated small-fibre neuropathy; preclinical work in kidney, autoimmune and neuro models. Not approved. | Investigational; not an approved medicine anywhere. The evidence base is preclinical, and a 2025 systematic review noted the absence of controlled human trials. |
| Reported safety signals | Phase 2 studies reported it as well tolerated over the trial periods; no long-term data. | No controlled human safety data; published findings are from animal and cell models. |
| A key study | A 28-day phase 2b randomised trial of 64 subjects measured corneal nerve fibre abundance with cibinetide. (Invest Ophthalmol Vis Sci 2017, PMID 28475703) | In cultured tendon fibroblasts, BPC-157 increased cell survival, outgrowth and migration in vitro. (J Appl Physiol (1985) 2011, PMID 21030672) |
WHEN TO RESEARCH WHICH
ARA-290 has small human trials in neuropathy; BPC-157 has a wide preclinical repair literature. Both are discussed here strictly as research compounds; nothing on this page is medical advice or a dosing guide.
REFERENCES (PUBMED)
- [ARA-290] Cibinetide Improves Corneal Nerve Fiber Abundance in Patients With Sarcoidosis-Associated Small Nerve Fiber Loss and Neuropathic Pain — Invest Ophthalmol Vis Sci 2017. PMID 28475703
- [ARA-290] Targeting the innate repair receptor to treat neuropathy — Pain Rep 2016. PMID 29392190
- [ARA-290] ARA290, a non-erythropoietic EPO derivative, attenuates renal ischemia/reperfusion injury — J Transl Med 2013. PMID 23302512
- [BPC-157] The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration — J Appl Physiol (1985) 2011. PMID 21030672
- [BPC-157] Modulatory effect of gastric pentadecapeptide BPC 157 on angiogenesis in muscle and tendon healing — J Physiol Pharmacol 2009. PMID 20388964
- [BPC-157] Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing — Cell Tissue Res 2019. PMID 30915550
FREQUENTLY ASKED
What is the difference between ARA-290 and BPC-157?
ARA-290 (cibinetide) is built from erythropoietin but does not raise red-cell counts; it targets the innate repair receptor and was trialled in neuropathy. BPC-157 is a gastric peptide studied in preclinical tissue-healing models.
What is the regulatory status of ARA-290 and BPC-157?
ARA-290: Phase 2 trials in sarcoidosis- and diabetes-associated small-fibre neuropathy; preclinical work in kidney, autoimmune and neuro models. Not approved. BPC-157: Investigational; not an approved medicine anywhere. The evidence base is preclinical, and a 2025 systematic review noted the absence of controlled human trials.
What safety signals have been reported?
ARA-290: Phase 2 studies reported it as well tolerated over the trial periods; no long-term data. BPC-157: No controlled human safety data; published findings are from animal and cell models.
Which studies is this comparison based on?
For ARA-290: “Cibinetide Improves Corneal Nerve Fiber Abundance in Patients With Sarcoidosis-Associated Small Nerve Fiber Loss and Neuropathic Pain” (PMID 28475703); “Targeting the innate repair receptor to treat neuropathy” (PMID 29392190); “ARA290, a non-erythropoietic EPO derivative, attenuates renal ischemia/reperfusion injury” (PMID 23302512). For BPC-157: “The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration” (PMID 21030672); “Modulatory effect of gastric pentadecapeptide BPC 157 on angiogenesis in muscle and tendon healing” (PMID 20388964); “Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing” (PMID 30915550).
MORE COMPARISONS
All products supplied for research purposes only. Not for human consumption.
In stock · ships from South Africa
Shop this comparison
Supplied for laboratory research only · not for human use